Skip to main
BAX

Baxter (BAX) Stock Forecast & Price Target

Baxter (BAX) Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 0%
Buy 22%
Hold 67%
Sell 11%
Strong Sell 0%

Bulls say

Baxter International's Healthcare Systems & Technologies segment experienced notable year-over-year sales growth, with increases of approximately 6% and 2% in the first two quarters of 2025, alongside projected growth of around 4% and 2% for the subsequent quarters. The company has benefited from effective pricing initiatives that are expected to yield an approximate 100 basis points contribution to sales growth for both 2024 and 2025. Additionally, the strategic acquisition of Hillrom has enhanced Baxter's product offerings, positioning the company to capture further market opportunities in the healthcare sector.

Bears say

Baxter International experienced a disappointing performance in the second quarter of 2025, with sales, margins, and earnings per share (EPS) all falling below consensus expectations. This underperformance stems from ongoing operational challenges that persisted throughout 2021-2023, characterized by both external pressures and internal missteps, which have resulted in mixed quarterly results and negative guidance revisions. Additionally, the company reported gross margins of 40.7% and operating margins of 15.1%, both of which were significantly below consensus estimates, driven by sales softness and manufacturing inefficiencies.

Baxter (BAX) has been analyzed by 9 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 22% recommend Buy, 67% suggest Holding, 11% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Baxter and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Baxter (BAX) Forecast

Analysts have given Baxter (BAX) a Hold based on their latest research and market trends.

According to 9 analysts, Baxter (BAX) has a Hold consensus rating as of Dec 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Baxter (BAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.